Kamada Ltd’s Promising Phase III Trial: A Potential Game-Changer for Alpha-1 Antitrypsin Deficiency

Kamada Ltd ((KMDA)) announced an update on their ongoing clinical study.

Study Overview: Kamada Ltd is conducting a Phase III clinical trial titled Prospective Phase 3 Multi-center 2-Year Placebo Controlled Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation 80 mg/Day in Alpha-1 Antitrypsin Deficiency With Moderate and Severe Airflow Limitation Followed by a 2-Year Open Label Extension. The study aims to assess whether Kamada-AAT for inhalation can slow lung disease progression in patients with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition causing lung disease.

Intervention/Treatment: The study tests Kamada’s Alpha 1-Antitrypsin product, administered via inhalation using an electronic nebulizer. The goal is to determine if daily inhalation of 80 mg can prevent or slow the worsening of lung function and density.

Study Design: This interventional study is randomized with a parallel assignment. It features a quadruple masking model, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded. The primary purpose is treatment, with participants receiving either the active drug or a placebo for two years, followed by two years of open-label treatment.

Study Timeline: The study began on December 17, 2019, and is currently recruiting. The last update was submitted on August 27, 2025. These dates are crucial for tracking the study’s progress and potential impact on Kamada’s strategic goals.

Market Implications: This study’s progress could significantly influence Kamada Ltd’s stock performance, as successful results may enhance investor confidence and market position. The trial’s outcome will also be closely watched by competitors in the respiratory treatment market, potentially affecting industry dynamics.

The study is ongoing, with further details available on the ClinicalTrials portal.